

100,000 VOICES

Campaign against Cancer Drugs Fund (CDF) cuts

The drug Regorafenib (Stivarga®) was approved in 2014 for support by the UK Cancer Drugs Fund as third line treatment for patients with advanced Gastro-Intestinal Stromal Tumour (GIST), a rare type of cancer found in the digestive system. For more on GIST see <http://www.gistsupportuk.com>

Regorafenib is used to treat GIST cancer when that is unresponsive to other drugs
Regorafenib is very successful in stopping tumour growth and shrinkage
Regorafenib is better tolerated in many patients than Imatinib or Sunitinib
Younger patients respond well to Regorafenib when other treatments have not worked
Regorafenib patients live considerably longer, providing invaluable time with families

**On 12 March 2015 Regorafenib is being de-listed from the Cancer Drugs Fund.
De-listing means patients die sooner as their cancer grows out of control.
But we know it works, so de-listing Regorafenib is not acceptable.**

100,000 Voices — The Campaign

On Wednesday 4 March the 100,000 VOICES campaign was launched in London
We need 100,000 signatures on an e-petition to stop the withdrawal of CDF support.

**Please join us:
Use twitter or facebook to spread the word
Write to your MP**